Canada \u00b7 Quebec coverage
Wegovy in Quebec: is it covered by RAMQ?
The short answer: no. Wegovy is not on the RAMQ List of Medications, Quebec's public plan excludes drugs whose purpose is weight loss, and INESSS recommended against listing it in February 2026. You can still get Wegovy with a prescription; whether anyone else pays depends on your private plan. Here is what Quebec's documents say, with links so you can check them.
Checked against Health Canada's Drug Product Database on October 15, 2026, and the RAMQ List of Medications of October 22, 2026 and the INESSS notice of February 2026.
Looking for Ozempic instead? It is a RAMQ exception drug for type 2 diabetes: Is Ozempic covered by RAMQ?
Wegovy and Ozempic in Quebec at a glance
| Wegovy | Ozempic | |
|---|---|---|
| Ingredient | Semaglutide | Semaglutide |
| Canadian indication | Chronic weight management | Type 2 diabetes |
| RAMQ List of Medications | Not listed | Exception drug for type 2 diabetes, prior authorization |
| INESSS position | Refusal, February 2026 (therapeutic value not recognized for the use assessed) | Listed with conditions (notice of February 2024) |
| Covered by RAMQ for weight loss? | No | No |
Check the current RAMQ Liste des médicaments (latest edition October 22, 2026; next scheduled November 19, 2026). Listings and conditions change.
What INESSS decided in February 2026
Because weight-loss drugs are excluded from Quebec's public plan, the manufacturer asked INESSS to assess Wegovy for a narrower use: improving cardiometabolic outcomes in people with a BMI of 35 or more and one or more weight-related conditions. INESSS recommended refusal because it did not recognize the therapeutic value for that use. Its main points:
- The evidence came mainly from the STEP trials, which were designed to measure weight loss in a broader population (BMI of 30 or more, or 27 or more with a weight-related condition).
- Systolic blood pressure was the only key secondary outcome that wasn't about weight. It fell significantly versus placebo, which clinicians consulted called meaningful.
- Drops in LDL cholesterol were marginal and not considered clinically meaningful; blood sugar and other lipids were only exploratory outcomes.
- Effects on heart attacks, strokes and sleep apnea weren't assessed for this use, which clinicians regretted.
- Clinicians consulted found Wegovy generally well tolerated, mostly with digestive side effects.
The same notice records that obesity affected about 33% of Canadian adults in 2022 to 2024, up from 25% in 2016 to 2019, and that public weight-management and nutrition programs in Quebec are limited or nearly nonexistent.
Why no province covers Wegovy
Quebec isn't alone. In June 2025, Canada's Drug Agency recommended public coverage only for adults with a BMI of 27 or more and established cardiovascular disease, and only with a lower price. Price talks through the pan-Canadian Pharmaceutical Alliance then ended without an agreement, as BC's December 2025 decision records. Quebec runs its own review through INESSS, and reached a refusal on its own terms.
Other provinces: Is Wegovy covered by OHIP? · Is Wegovy covered in Canada?
How to get Wegovy in Quebec
- See a Quebec physician or nurse practitioner who can assess whether Wegovy suits you. Only a prescriber can decide that.
- Fill the prescription at a licensed Quebec pharmacy. Wegovy is authorized by Health Canada.
- Ask your group insurer whether Wegovy is covered, and whether it needs prior authorization. Quebec residents with access to a group plan generally must be covered by it.
- If your plan says no, ask your pharmacist whether a covered alternative or the generic version changes anything for your plan.
More steps: Wegovy in Canada.
RAMQ terms in French
| French | What it means |
|---|---|
| Refus d'inscription | Refusal to list: INESSS recommends the drug not be added to the RAMQ list |
| Valeur thérapeutique non reconnue | Therapeutic value not recognized for the use assessed |
| Produits exclus | Products excluded from the public plan, including drugs whose purpose is weight loss |
| Paramètres cardiométaboliques | Cardiometabolic measures such as blood pressure, cholesterol and blood sugar |
| Assurance collective | Private group insurance |
Watch out for “research” semaglutide
Semaglutide sold online as a “research chemical” isn't an authorized drug, isn't covered by any plan and isn't a legal shortcut. Health Canada's April 2026 advisory warns against injecting it.
What semaglutide users report
- 49 published anonymous semaglutide confessions; 7 mention at least one side effect.
- 19 mention Ozempic, Wegovy or Rybelsus by name.
- Among confessions that state a weight change in pounds, the median reported is 51 lb. Self-reported, unverified.
Most-mentioned side effects (share of semaglutide confessions):
- Burping: 6.1% (3)
- Vomiting: 6.1% (3)
- Anxiety or panic: 4.1% (2)
- Nausea: 4.1% (2)
- Constipation: 2% (1)
Counts are phrase mentions in anonymous accounts, not diagnoses or clinical rates. Full breakdown and methodology: Semaglutide hub.
By province and city
Related
- GLP-1 drugs in Canada · Ozempic alternatives in Canada · Orforglipron in Canada
- Peptides and Ozempic in Quebec · Montreal
- Is Ozempic covered by RAMQ?
- Is Mounjaro covered by RAMQ?
- Is Wegovy covered in Canada?
- Is Wegovy covered by OHIP?
- Generic semaglutide in Canada
- Ozempic vs Wegovy in Canada
- Peptides in Canada hub
Frequently asked questions
- Is Wegovy covered by RAMQ?
- No. Wegovy is not on the RAMQ List of Medications. Quebec's public drug plan excludes drugs whose purpose is weight loss, and in February 2026 INESSS recommended against listing Wegovy for the narrower cardiometabolic use the manufacturer asked for.
- Why did INESSS refuse Wegovy?
- The manufacturer asked INESSS to list Wegovy to improve cardiometabolic outcomes in people with a BMI of 35 or more and at least one weight-related condition. INESSS found the evidence mostly measured weight loss, that blood pressure was the only key non-weight outcome, and that heart attacks, strokes and sleep apnea were not assessed for that use. It concluded the therapeutic value was not recognized.
- Can I get Wegovy in Quebec?
- Yes, with a prescription. Wegovy is authorized by Health Canada and dispensed by Quebec pharmacies. Coverage is the issue, not availability: the public plan won't pay for it, and private group plans decide for themselves.
- Do private plans in Quebec cover Wegovy?
- Some do. Quebec group plans must cover at least the drugs on the RAMQ list, and many cover more, sometimes with prior authorization or a weight-management rider. Check your plan booklet or ask your insurer.
- Is Ozempic covered in Quebec when Wegovy isn't?
- Ozempic is a RAMQ exception drug for type 2 diabetes under specific conditions, with prior authorization. It is not covered for weight loss.
- Is generic Wegovy covered in Quebec?
- Health Canada authorized the first generic semaglutide for weight management in June 2026. Quebec's exclusion applies to drugs whose purpose is weight loss, so a generic for that use faces the same rule. Ask your pharmacist or insurer.
- Does this page recommend a clinic, product or dose?
- No. We don't list clinics, sellers, prices or doses, and nothing here is medical advice. Talk to a Quebec prescriber or pharmacist.
Sources
Last reviewed November 11, 2026. How we source pages: editorial policy.
- INESSS notice to the minister on Wegovy, February 2026 (inesss.qc.ca)
- RAMQ: Liste des médicaments (ramq.gouv.qc.ca)
- Canada's Drug Agency: semaglutide (Wegovy) reimbursement review (cda-amc.ca)
- BC PharmaCare decision on Wegovy, noting the pCPA outcome (gov.bc.ca)
- Health Canada: first generic semaglutide for weight loss (canada.ca)
General information only — not medical, legal or regulatory advice. Peptide Confessions does not sell, source or recommend any product or vendor, and nothing here is dosing guidance. Speak with a licensed Canadian healthcare professional or pharmacist about any medication. Editorial process →